The European Medicines Agency (EMA for its acronym in English) has announced this Tuesday that it begins the evaluation of the Spanish vaccine
Hipra
.
The vaccine is based on
two structurally similar recombinant proteins
, one corresponding to the
alpha variant and the other corresponding to the beta variant
, which join together to form a single structure called a dimer, and which are accompanied by an adjuvant that increases the immune response.
This combination is capable of generating an immune response against one of the proteins of the SARS-CoV-2 virus, known as protein S (for spike, also called spike protein in Spanish).
This platform is the same one that has been used for
the Novavax and Sanofi/GSK vaccines
, which are already in the process of being evaluated for their potential authorization by the European Medicines Agency (EMA), but difference from them, express
Conforms to The Trust Project criteria
Know more
Health Spanish researchers discover a key 'shuttle' in cell and tissue growth
HealthNew step towards the control of insulin-dependent diabetes: functional pancreatic islets from stem cells
HealthA stool test to detect pancreatic cancer
See links of interest
War Ukraine Russia direct
last minute transportation strike
Last News
Oscar Winners 2022
Will Smith
Where to watch Oscar movies
Topics
Work calendar 2022
Las Palmas - Leganes
Live, Marin Cilic - Carlos Alcaraz